Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Arvinas in a report issued on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now forecasts that the ...

Arvinas (ARVN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...

Arvinas’ cash burn and lack of pipeline candidates hurt its outlook. See why ARVN stock is a sell, despite a healthy cash ...

Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” ...

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and ...

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

Guggenheim analyst Michael Schmidt maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) yesterday and set a price target ...

Wells Fargo analyst Derek Archila lowered the firm’s price target on Arvinas (ARVN) to $26 from $60 and keeps an Overweight rating on the ...

Arvinas shares plunged 45% after its Pfizer-partnered breast cancer drug, vepdegestrant, failed to delay cancer progression for all patients. The drug only met its goal for a subset of patients with a ...